GFN•TV will bring the conference's platform for rational and inclusive debate on the future role of safer nicotine products and tobacco harm reduction to an audience all year round. GFN•TV will also be broadcasting live from Warsaw in June. Tune in to hear world-leading experts, tobacco harm reduction advocates and nicotine consumers discuss the latest scientific, regulatory and policy developments. From our unique annual event, to year-round reporting of the issues that matter in tobacco harm reduction, GFN has got it covered.
A South African Perspective on Tobacco Harm Reduction | GFN Voices 2024 #5
In today's GFN Voices episode, Kurt Yeo explore the crucial relationship between economics, health, and tobacco harm reduction. With a focus on South Africa, we delve into the burden tobacco places on public health, the economic challenges it creates, and how harm reduction strategies could be the key to a healthier future.
📅 6 Sep 2024
What's the Truth about Nicotine? | GFN Voices 2024 #4
In this insightful discussion, Liza Katsiashvili, Andrzej Fal and Ethan Nadelmann tackle the growing misconceptions surrounding vaping and tobacco harm reduction. Learn how misinformation, fueled by media and powerful institutions like the WHO, is shaping public opinion and preventing effective harm reduction strategies.
📅 3 Sep 2024
From Oversight to Action: Addressing Smoking Rates in Vulnerable Populations | #GFN24
English subtitles are available through the YouTube 'CC' button!
It is widely recognized that smoking rates among key and vulnerable populations surpass those of other groups. However, across much of the globe, support services often overlook this issue. Consequently, many will face mortality not due to their substance use or mental health conditions, but rather as a result of smoking-related diseases. This session aims to discuss the reasons for this oversight, with a particular emphasis on Eastern Europe and Central Asia, and to generate ideas for effective interventions to address this critical issue.
📅 27 Aug 2024
Harnessing the power of physicians, consumer advocates and regulators to promote THR | #GFN24
In this insightful panel discussion, experts explore the complex relationship between healthcare professionals and users within the context of harm reduction. The panel delves into the challenges of communicating harm reduction strategies to society and policymakers, while addressing the needs and perspectives of both doctors and users.
What are the key insights from Global Forum on Nicotine? | GFN Voices 2024 #3
In this video, we dive into the highlights and key takeaways from a recent global advocacy conference. Hear from Michael Landl as he shares his favorite sessions, including an inspiring talk by Ethan Nadelmann. Learn about the importance of community, shared experiences, and effective strategies across different countries.
Featuring Michael Landl, Jarkyn Shadymanova and Pranay Ratna Sakya.
For Tobacco Harm Reduction (THR) to become widespread, affordable and appealing, reduced-risk alternatives to harmful tobacco products must be legally available and accessible. Achieving this requires sustained, substantial investment. The pace of harm reduction is closely tied to investment levels, influenced by potential risks and returns. Regulatory risk and uncertainty increase the returns required by investors, reducing available capital. Consequently:
- Reduced Investment in Product Development: Lower investment hinders the development of safer and more appealing products supported by scientific research. Without this, regulators are unlikely to consider them as effective harm-reduction solutions, and existing RRPs do not appeal to most smokers.
- Limited Accessibility in the Global South: Insufficient investment in cost reduction makes these products inaccessible to consumers in the Global South, home to 80% of harmful tobacco users.
- Hesitancy to Enter High-Risk Markets: Companies and investors are less likely to enter markets with high regulatory risk.
GFN 2024 Workshop - hosted by Pieter Vorster with panellists: Sud Patwardhan, Jonathan Fell and Marina Murphy
📅 13 Aug 2024
Regulation round up: global perspectives - Workshop | #GFN24
Welcome to our panel discussion on the global regulatory landscape for tobacco harm reduction and novel nicotine products. Hosted by Barnaby Page from Tamarind Intelligence, publisher of E-cig Intelligence and Tobacco Intelligence, the panel features experts from around the world including Peter Beckett from the UK, Lindsey Stroud from the USA, Michael Landl from Austria, and David Yu from China.
In this session, we dive into the current state of tobacco harm reduction, discuss novel nicotine products, and explore the regulatory environments across different regions.
Topics covered include:
- Overview of global tobacco harm reduction strategies
- Regulatory challenges and opportunities in different countries
- Perspectives on novel nicotine products
- Future trends and predictions for tobacco harm reduction
GFN 2024 Workshop - hosted by Barnaby Page with panellists: Michael Landl, Peter Beckett, Lindsey Stroud and David Yu
📅 9 Aug 2024
Lessons from GFN on Tobacco Harm Reduction | GFN Voices 2024 #2
We delve into the key insights and discussions from the Global Forum on Nicotine (GFN). Our expert speakers share their experiences and reflections on the evolution of tobacco harm reduction, exploring the intersection of science, economics, and politics. Learn about the challenges faced, the progress made, and the future of tobacco harm reduction in public health. Featuring Clive Bates, Gerry Stimson, Stefan Mathisson and Analucia Saraiva.
📅 6 Aug 2024
What does 'independent' mean, in relation to THR science? - Workshop | #GFN24
Scientific data are critical to our understanding of the harm reduction potential of novel tobacco and nicotine products. Such data can be used in shaping evidence-based regulation and to inform consumers of the relative risks of tobacco product use. Increasingly, there are calls to preclude data generated by manufacturers in informing policy, as this data is seen by some as not ‘independent’ and biased by commercial goals.
This panel session will explore: - What does independent mean when it comes to tobacco harm reduction science? - Why might manufacturers’ data not be acceptable? - Are manufacturers’ data on nicotine products any different from pharmaceutical industry data on novel drugs? - Does not being independent mean that we should not trust the data? Should we ignore it? Or just acknowledge it and move on without looking at it? - What are the dangers of ignoring evidence seen as ‘dependent’ and what does that mean for THR? Are there unintended consequences? - How do we move forward from here? How do we make sure both dependent and independent evidence is used to inform consumers and to help shape regulation?
GFN 2024 Workshop - hosted by Ian Fearon with panellists: Marewa Glover, Sarah Cooney, George Hardie and Colin Mendelsohn
📅 2 Aug 2024
GFN.TV Interviews | WILLING IGNORANCE | Reluctance to Promote Nicotine Vapes for Harm Reduction
Tragically, those who should know better—medical doctors, public health officials, and the media—are reluctant to promote nicotine vaping as a tool for harm reduction. Instead, they make a deliberate choice to ignore or avoid acknowledging the truth about vaping. This problem is widespread, including in Latin America. Learn more in this special hybrid English/Spanish episode of GFN Interviews.
Featuring: DR. DIEGO VERRASTRO Physician, General and Emergency Surgery Co-founder, Latin American Network for THR, RELDAT.org
JEFFREY ZAMORA President, Asovape Costa Rica & of ARDT Iberoamerica Director of Social Media, INNCO @jeffzam8
